Crystal Research CEO Speaks With ABC News/Al Jazeera on JNJ Settlement

Posted by Laura Swartz

November 7, 2013 at 1:18 PM

On Tuesday, Jeffrey Kraws, senior pharmaceutical analyst at Crystal Research Associates, spoke with ABC News and Al Jazeera television regarding Johnson & Johnson’s $2.2 billion settlement for unlawfully marketing Risperdal, an anti-psychotic drug. Risperdal is FDA approved to treat schizophrenia but was illegally marketed to doctors and nursing homes as a treatment for elderly patients with dementia. The settlement included criminal fines totaling $485 million and civil fines of over $1.7 billion, which included payments to whistleblowers.  

Mr. Kraws spoke with Al Jazeera from New York City in a live segment airing overseas shortly after 4 PM ET on Tuesday. Among other questions, Kraws explains some of the ethical and brand image ramifications of JNJ’s actions and answers how the drug giant was able to use a system of internal as well as third-party players, kickbacks, and unsubstantiated product claims put forth over the years despite repeated warnings from the FDA.  

Read More

Topics: Crystal Research Associates, Newsworthy Events, Al Jazeera, ABC News

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic